Compare Stocks: SGIOY, TAK, BAYRY, and UCBJF

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$14.19	$14.03	$7.48 ▼ $15.23	$55.77B	0.56	665,688 shs	351,184 shs
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$9.25	$8.93	$7.65 ▼ $12.00	$15.74B	0.08	77,898 shs	54,723 shs
TAK Takeda Pharmaceutical	$18.46 +0.1%	$17.36	$12.99 ▼ $18.90	$59.12B	-0.07	2.30 million shs	1.50 million shs
UCBJF UCB	$255.34	$273.21	$225.65 ▼ $345.39	$48.26B	0.47	721 shs	72 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	0.00%	-0.49%	-1.73%	+39.25%	+72.21%
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	0.00%	+2.32%	+3.93%	+8.06%	+2.89%
TAK Takeda Pharmaceutical	0.00%	+2.56%	+5.72%	+17.62%	+19.91%
UCBJF UCB	0.00%	+1.78%	-5.20%	-17.66%	+3.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$14.19	$14.03	$7.48 ▼ $15.23	$55.77B	0.56	665,688 shs	351,184 shs
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$9.25	$8.93	$7.65 ▼ $12.00	$15.74B	0.08	77,898 shs	54,723 shs
TAK Takeda Pharmaceutical	$18.46 +0.1%	$17.36	$12.99 ▼ $18.90	$59.12B	-0.07	2.30 million shs	1.50 million shs
UCBJF UCB	$255.34	$273.21	$225.65 ▼ $345.39	$48.26B	0.47	721 shs	72 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	0.00%	-0.49%	-1.73%	+39.25%	+72.21%
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	0.00%	+2.32%	+3.93%	+8.06%	+2.89%
TAK Takeda Pharmaceutical	0.00%	+2.56%	+5.72%	+17.62%	+19.91%
UCBJF UCB	0.00%	+1.78%	-5.20%	-17.66%	+3.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAYRY Bayer Aktiengesellschaft	3.13	Buy	N/A	N/A
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	3.33	Buy	N/A	N/A
TAK Takeda Pharmaceutical	2.75	Moderate Buy	N/A	N/A
UCBJF UCB	2.71	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest SGIOY, TAK, BAYRY, and UCBJF Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/2/2026	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2026	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/3/2026	UCBJF UCB	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/30/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
7/22/2026	UCBJF UCB	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/14/2026	SGIOY Shionogi & Co., Ltd. Unsponsored ADR	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/10/2026	BAYRY Bayer Aktiengesellschaft	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/2/2026	BAYRY Bayer Aktiengesellschaft	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/29/2026	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/23/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
6/15/2026	SGIOY Shionogi & Co., Ltd. Unsponsored ADR	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAYRY Bayer Aktiengesellschaft	$51.55B	1.08	$2.18 per share	6.50	$7.50 per share	1.89
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$3.32B	4.74	$0.91 per share	10.22	$6.54 per share	1.41
TAK Takeda Pharmaceutical	$28.32B	2.09	$3.11 per share	5.94	$15.41 per share	1.20
UCBJF UCB	$5.27B	9.16	$10.97 per share	23.28	$50.52 per share	5.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAYRY Bayer Aktiengesellschaft	-$4.10B	-$0.51	N/A	10.59	4.43	-3.80%	16.77%	4.53%	11/3/2026 (Estimated)
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$1.35B	$1.00	9.25	11.86	3.42	46.67%	16.47%	12.92%	10/26/2026 (Estimated)
TAK Takeda Pharmaceutical	-$1.01B	$0.34	54.29	14.20	N/A	3.80%	10.95%	5.34%	10/29/2026 (Estimated)
UCBJF UCB	$371.23M	N/A	N/A	36.17	N/A	N/A	N/A	N/A	N/A

Latest SGIOY, TAK, BAYRY, and UCBJF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	BAYRY Bayer Aktiengesellschaft	$0.23	$0.29	+$0.06	$0.07	$12.31 billion	$12.53 billion
8/3/2026	Q1 2027	SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$0.18	$0.36	+$0.18	$0.36	$970.69 million	$1.04 billion
7/30/2026	Q1 2027	TAK Takeda Pharmaceutical	$0.41	$0.95	+$0.54	$0.22	$7.13 billion	$7.50 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAYRY Bayer Aktiengesellschaft	$0.02	0.14%	N/A	N/A	N/A
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$0.14	1.51%	N/A	14.00%	N/A
TAK Takeda Pharmaceutical	$0.48	2.60%	-6.89%	141.18%	N/A
UCBJF UCB	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAYRY Bayer Aktiengesellschaft	1.05	1.04	0.67
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	0.01	1.58	1.46
TAK Takeda Pharmaceutical	0.58	1.14	0.62
UCBJF UCB	0.33	1.19	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAYRY Bayer Aktiengesellschaft	N/A
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	1.92%
TAK Takeda Pharmaceutical	9.17%
UCBJF UCB	N/A

Insider Ownership

Company	Insider Ownership
BAYRY Bayer Aktiengesellschaft	N/A
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	N/A
TAK Takeda Pharmaceutical	0.04%
UCBJF UCB	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAYRY Bayer Aktiengesellschaft	88,078	3.93 billion	N/A	Not Optionable
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	4,955	1.70 billion	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,000	3.20 billion	3.20 billion	Optionable
UCBJF UCB	9,083	189.02 million	N/A	Not Optionable

SGIOY, TAK, BAYRY, and UCBJF Headlines

Recent News About These Companies

Stacy Ku Initiates Buy on UCB, Citing Attractive Valuation and Early Bimzelx-Driven Growth Inflection

August 3, 2026 | tipranks.com

Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion

May 3, 2026 | reuters.com

Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15B

April 17, 2026 | seekingalpha.com

Belgium's UCB in autoimmune drug deal with Antengene

March 3, 2026 | reuters.com

Day by Day maintains UCB (UCBJF) buy recommendation

December 17, 2025 | msn.com

UCB price target raised to EUR 300 from EUR 230 at JPMorgan

December 8, 2025 | msn.com

UCB removed from European Conviction List at Goldman Sachs

November 4, 2025 | msn.com

UCB assumed with an Underperform at Jefferies

October 27, 2025 | msn.com

UCB announces new three-year data from Phase 3 trials on BIMZELX

October 26, 2025 | msn.com

United Community Banks, Inc. (UCB) Q3 2025 Earnings Call Transcript

October 22, 2025 | seekingalpha.com

UCB price target raised to EUR 290 from EUR 220 at Berenberg

October 14, 2025 | msn.com

UCB price target raised to EUR 285 from EUR 250 at Deutsche Bank

October 6, 2025 | msn.com

MoonLake rebounds despite downgrades prompted by trial setback

September 30, 2025 | msn.com

UCB price target raised to EUR 240 from EUR 220 at Morgan Stanley

September 8, 2025 | msn.com

UCB SA (UCBJF) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

United Community Banks, Inc. (UCB) Q2 2025 Earnings Call Transcript

July 23, 2025 | seekingalpha.com

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

May 20, 2025 | finance.yahoo.com

United Community Banks, Inc. (UCB) Q1 2025 Earnings Call Transcript

April 22, 2025 | seekingalpha.com

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

April 3, 2025 | finance.yahoo.com

UCB Convening Notice to the General Meeting of the Shareholders 2025

March 21, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SGIOY, TAK, BAYRY, and UCBJF Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$14.19 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Shionogi & Co., Ltd. Unsponsored ADR OTCMKTS:SGIOY

$9.25 0.00 (0.00%)

As of 09/4/2026 03:58 PM Eastern

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Takeda Pharmaceutical NYSE:TAK

$18.46 +0.01 (+0.05%)

Closing price 09/4/2026 03:58 PM Eastern

Extended Trading

$18.69 +0.23 (+1.27%)

As of 08:52 AM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

UCB OTCMKTS:UCBJF

$255.34 0.00 (0.00%)

As of 09/4/2026 03:20 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGIOY, TAK, BAYRY, and UCBJF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGIOY, TAK, BAYRY, and UCBJF Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGIOY, TAK, BAYRY, and UCBJF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SGIOY, TAK, BAYRY, and UCBJF Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

Shionogi & Co., Ltd. Unsponsored ADR OTCMKTS:SGIOY

Takeda Pharmaceutical NYSE:TAK

UCB OTCMKTS:UCBJF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGIOY, TAK, BAYRY, and UCBJF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGIOY, TAK, BAYRY, and UCBJF Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGIOY, TAK, BAYRY, and UCBJF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SGIOY, TAK, BAYRY, and UCBJF Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

Shionogi & Co., Ltd. Unsponsored ADR OTCMKTS:SGIOY

Takeda Pharmaceutical NYSE:TAK

UCB OTCMKTS:UCBJF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools